Status:

UNKNOWN

The Effect of a Dietary Supplement Rich in Nitric Oxide in Patients Diagnosed With Primary Ciliary Dyskinesia.

Lead Sponsor:

The University of Texas Health Science Center, Houston

Conditions:

Primary Ciliary Dyskinesia

Eligibility:

All Genders

4-99 years

Phase:

NA

Brief Summary

The purpose of this study is to determine the effect of a dietary supplement rich in nitric oxide (NO) on nasal nitric oxide and fractional exhaled nitric oxide (FeNO),on ciliary beat frequency assess...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Experimental group:
  • PCD patients
  • Control Group:
  • patients with no known chronic lung disease
  • 18 years to 99 years
  • Exclusion Criteria(both PCD patients and control group):
  • any other pulmonary co-morbidities and diseases entities like cystic fibrosis, nasal sinus surgery, nasal sinus hypoplasia/aplasia, deviated nasal septum, nasal polyps and with upper respiratory tract infection
  • patients allergic to beet
  • a known prolonged bleeding disorder.

Exclusion

    Key Trial Info

    Start Date :

    July 31 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    May 1 2024

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT04489472

    Start Date

    July 31 2019

    End Date

    May 1 2024

    Last Update

    May 12 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    The University of Texas Health Science Center at Houston

    Houston, Texas, United States, 77030